{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:51:48Z","timestamp":1793242308342,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Ligand Pharmaceuticals"},{"name":"NCI MDACC Core","award":["CA16672-22"],"award-info":[{"award-number":["CA16672-22"]}]},{"name":"NCI MDACC Core","award":["NCI (R21-CA74117)"],"award-info":[{"award-number":["NCI (R21-CA74117)"]}]},{"name":"NCI MDACC Core","award":["NIAMS K24 CA 86"],"award-info":[{"award-number":["NIAMS K24 CA 86"]}]},{"name":"NCI MDACC Core","award":["815"],"award-info":[{"award-number":["815"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1016\/j.clml.2012.01.011","type":"journal-article","created":{"date-parts":[[2012,4,21]],"date-time":"2012-04-21T17:14:58Z","timestamp":1335028498000},"page":"180-185","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Pilot Study of Denileukin Diftitox Alternate Dosing Regimen in Patients With Cutaneous Peripheral T-Cell Lymphomas"],"prefix":"10.1016","volume":"12","author":[{"given":"Rakhshandra","family":"Talpur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Duvic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2012.01.011_bib1","series-title":"Classification of tumours of haematopoietic and lymphoid tissues","year":"2008"},{"key":"10.1016\/j.clml.2012.01.011_bib2","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.critrevonc.2008.10.011","article-title":"Current and future aggressive peripheral T-cell lymphoma treatment paradigms, biological features and therapeutic molecular targets","volume":"71","author":"Rodriguez","year":"2009","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"10.1016\/j.clml.2012.01.011_bib3","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Vose","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2012.01.011_bib4","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/oxfordjournals.annonc.a057673","article-title":"Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen","volume":"1","author":"Coiffier","year":"1990","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2012.01.011_bib5","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1182\/asheducation-2008.1.280","article-title":"Prognosis and primary therapy in peripheral T-cell lymphomas","author":"Savage","year":"2008","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2012.01.011_bib6","doi-asserted-by":"crossref","first-page":"1011a","DOI":"10.1182\/blood.V110.11.3452.3452","article-title":"Response and survival rates in patients with peripheral T-cell lymphoma treated with anthracycline-based regimens: a comprehensive meta-analysis","volume":"110","author":"Abouyabis","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.01.011_bib7","doi-asserted-by":"crossref","first-page":"4921","DOI":"10.1158\/1078-0432.CCR-10-1214","article-title":"Folotyn (pralatrexate injection) for the treatment of patients with relapsed or refractory peripheral T cell lymphoma: U.S. Food and Drug Administration drug approval summary","volume":"16","author":"Malik","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2012.01.011_bib8","doi-asserted-by":"crossref","first-page":"6756","DOI":"10.1182\/blood-2010-05-231548","article-title":"Peripheral T-cell lymphoma","volume":"117","author":"Foss","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2012.01.011_bib9","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2217\/14796694.4.4.457","article-title":"Optimizing denileukin diftitox (Ontak) therapy","volume":"4","author":"Duvic","year":"2008","journal-title":"Futures Oncol"},{"key":"10.1016\/j.clml.2012.01.011_bib10","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1073\/pnas.84.7.2002","article-title":"Interleukin 2 binding molecule distinct from the Tac protein: analysis of its role in formation of high-affinity receptors","volume":"84","author":"Robb","year":"1987","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clml.2012.01.011_bib11","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/sj.jid.5700122","article-title":"CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma","volume":"126","author":"Talpur","year":"2006","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clml.2012.01.011_bib12","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/S0959-8049(96)00327-9","article-title":"Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies","volume":"33","author":"Nichols","year":"1997","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clml.2012.01.011_bib13","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1200\/JCO.2001.19.2.376","article-title":"Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma","volume":"19","author":"Olsen","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2012.01.011_bib14","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1200\/JCO.2009.26.2386","article-title":"Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma","volume":"28","author":"Prince","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2012.01.011_bib15","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/archderm.138.1.42","article-title":"Quantifying skin disease burden in mycosis fungoides\u2013type cutaneous T-cell lymphomas: the severity-weighted assessment tool (SWAT)","volume":"138","author":"Stevens","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clml.2012.01.011_bib16","first-page":"3","article-title":"Complete response of a primary cutaneous CD30+ anaplastic large-cell lymphoma to denileukin diftitox","volume":"3","author":"Duvic","year":"2004","journal-title":"Case Studies in Lymphoma"},{"key":"10.1016\/j.clml.2012.01.011_bib17","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3816\/CLM.2008.n.005","article-title":"Cutaneous gamma\/delta T-cell lymphoma treated with radiation and denileukin diftitox","volume":"8","author":"Vidulich","year":"2008","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.1016\/j.clml.2012.01.011_bib18","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1210\/jc.2005-2839","article-title":"Thyrotoxicosis after denileukin diftitox therapy in patients with mycosis fungoides","volume":"91","author":"Ghori","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clml.2012.01.011_bib19","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1080\/10428190210183","article-title":"Treatment of refractory peripheral T-cell lymphoma with denileukin diftitox (Ontak)","volume":"43","author":"Talpur","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2012.01.011_bib20","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1002\/ajh.21177","article-title":"De novo maintenance therapy with denileukin diftitox (Ontak) in a patient with peripheral T cell lymphoma is associated with prolonged remission","volume":"83","author":"Wong","year":"2008","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2012.01.011_bib21","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1365-2141.2006.06457.x","article-title":"Phase II trial of denileukin diftitox for relapsed\/refractory T-cell non-Hodgkin lymphoma","volume":"136","author":"Dang","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2012.01.011_bib22","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0162-3109(97)00041-6","article-title":"Vascular leak syndrome: a side effect of immunotherapy","volume":"37","author":"Baluna","year":"1997","journal-title":"J Immunopharmacol"},{"key":"10.1016\/j.clml.2012.01.011_bib23","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1073\/pnas.96.7.3957","article-title":"Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome","volume":"96","author":"Baluna","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clml.2012.01.011_bib24","first-page":"4052","article-title":"Phase I immunotoxin trial in patients with B-cell lymphoma","volume":"51","author":"Vitetta","year":"1991","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2012.01.011_bib25","first-page":"2461","article-title":"Phase II study of denileukin diftitox (Ontak\u00ae) with CHOP chemotherapy in patients with newly-diagnosed aggressive T-cell lymphomas, the CONCEPT trial: interim analysis","volume":"108","author":"Foss","year":"2006","journal-title":"Blood (ASH Annual Meeting Abstracts)"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265012000481?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265012000481?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:22:49Z","timestamp":1761870169000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265012000481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S2152265012000481"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2012.01.011","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pilot Study of Denileukin Diftitox Alternate Dosing Regimen in Patients With Cutaneous Peripheral T-Cell Lymphomas","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2012.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}